Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through Kiniksa Pharmaceuticals’ 200-page disclosures can feel like reading lab notes in another language. Clinical trial protocols, ARCALYST revenue footnotes, and intricate risk factors are scattered across multiple forms—yet timing these details is critical when a single Phase 2 update can move the stock overnight.
Our platform turns that maze into a map. Stock Titan’s AI-powered summaries translate each Kiniksa Pharmaceuticals annual report 10-K simplified into plain English, highlight cash-burn trends in every Kiniksa Pharmaceuticals quarterly earnings report 10-Q filing, and flag Kiniksa Pharmaceuticals 8-K material events explained within minutes of hitting EDGAR. Need real-time signals? We stream Kiniksa Pharmaceuticals Form 4 insider transactions real-time so you can monitor executive confidence before key data drops. The result: you spend minutes, not hours, uncovering what matters.
- Track Kiniksa Pharmaceuticals insider trading Form 4 transactions and spot buying or selling patterns.
- Dive into Kiniksa Pharmaceuticals proxy statement executive compensation to see how milestones shape pay packages.
- Compare segments with a click using our Kiniksa Pharmaceuticals earnings report filing analysis.
Whether you’re understanding Kiniksa Pharmaceuticals SEC documents with AI for the first time or need a refresher before a call, our expert analysis covers every form type—10-K, 10-Q, 8-K, S-1, and more. Receive alerts the moment a Kiniksa Pharmaceuticals executive stock transactions Form 4 posts, and let our algorithm spotlight the trial endpoints, cash runway, and material agreements that drive valuation. Complex biotech filings, explained simply, updated in real time—so you can act with confidence.
Kiniksa Pharmaceuticals International, plc (KNSA) reported an insider equity transaction by its Chief Operating Officer on Form 4. On 11/17/2025, the COO exercised a share option for 6,500 Class A ordinary shares at an exercise price of $8.83 per share, then sold shares the same day in two broker-executed transactions under a pre-arranged Rule 10b5-1 trading plan dated April 29, 2024.
The sales included 645 shares at a weighted average price of $40.08 and 11,825 shares at a weighted average price of $41.30, both executed in multiple trades within stated price ranges. After these transactions, the COO directly beneficially owned 22,714 Class A ordinary shares and held 6,000 share options that are fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA): The Chairman & CEO reported bona fide gifts (Code G) of Class A ordinary shares. On 11/12/2025, 111,794 shares were gifted; on 11/13/2025, 60,000 shares were gifted. These entries were at a stated price of $0 per share.
After the transactions, reported holdings were 0 shares direct, and indirect balances included 51,794 shares held by The Anglia 2013 Revocable Trust, 60,000 shares held by The Patel Family Irrevocable Trust of 2025, and 109,795 shares held by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) disclosed a Form 4 showing its Chief Medical Officer executed pre‑planned transactions on 10/31/2025 under a Rule 10b5‑1 plan. The officer exercised options for 36,542 Class A ordinary shares at $3.80 and 46,000 shares at $8.83, then sold 82,542 shares at a weighted average price of $37.14 (trade range: $36.80–$37.675). Following these transactions, the filing reports 61,324 shares beneficially owned directly. The options exercised were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO exercised 100 share options at $30.93 and sold 100 Class A Ordinary Shares at $41.00, executed under a Rule 10b5-1 plan dated September 3, 2024. Following these trades, the officer directly owned 31,086 shares and held 19,900 options with an expiration of 09/19/2028. The option was fully vested and exercisable.
Kiniksa Pharmaceuticals International (KNSA) reported a profitable quarter. For Q3 2025, total revenue was $180.855 million, up from $112.214 million a year ago, driven entirely by higher net product revenue from ARCALYST in the U.S. Net income reached $18.435 million versus a loss of $12.693 million last year; diluted EPS was $0.23.
Operating expenses reflected ARCALYST profit sharing with Regeneron, with collaboration expenses at $63.307 million. Cost of goods sold was $20.257 million, R&D $24.166 million, and SG&A $49.104 million. Cash, cash equivalents and short‑term investments totaled $352.102 million as of September 30, 2025, and operating cash flow for the nine months was $84.091 million. Shareholders’ equity increased to $535.383 million from $438.436 million at year‑end.
Year‑to‑date, revenue was $475.437 million (vs. $300.703 million), with net income of $44.806 million (vs. a $34.305 million loss). The company terminated the mavrilimumab license with MedImmune effective May 22, 2025 and mutually terminated the Huadong mavrilimumab agreement; the ARCALYST Huadong agreement remains in place with $31.811 million recorded as non‑current deferred revenue.
Kiniksa Pharmaceuticals International, plc (KNSA) disclosed insider transactions by its Chairman & CEO under a Rule 10b5-1 plan. On 10/20–10/22/2025, the insider exercised 257,969 share options at $3.80 and sold an equal 257,969 Class A Ordinary Shares in brokered trades.
Weighted average sale prices reported include $38.81 (range $38.14–$39.135), $39.32 (range $39.14–$39.55), $38.77 (range $38.49–$39.235), and $38.83 (range $38.495–$39.255). Following these transactions, direct holdings were 111,794 shares. An additional 109,795 shares were held indirectly by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) insider transaction: The company’s Chief Accounting Officer exercised multiple vested stock options and sold shares on 10/20/2025 pursuant to a Rule 10b5-1 plan executed on May 24, 2025. Option exercises added 791 shares at $15.50, 6,195 at $12.97, 9,831 at $11.10, 9,831 at $11.97, and 12,787 at $10.76.
The insider then sold 37,255 shares at a weighted average price of $38.72 (trades ranged from $38.14 to $39.135) and 13,235 shares at a weighted average price of $39.31 (trades ranged from $39.145 to $39.57). After these transactions, the insider beneficially owned 27,046 Class A ordinary shares, held directly. The filing notes the options were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported a Form 4 for its COO. On 10/14/2025, the officer exercised 6,500 options at $8.83 and sold 11,815 shares at a $37.65 weighted average and 553 shares at $37.99, executed through multiple trades under a Rule 10b5-1 plan adopted on April 29, 2024. Following these transactions, the officer beneficially owned 28,684 Class A shares directly and 12,500 options remained held. The reported option was fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) officer Michael R. Megna reported changes in beneficial ownership on
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
